Intravenous therapy and vein access devices market seen reaching $48.1B by 2030

The intravenous therapy and vein access devices market is projected to grow from $33.15 billion in 2025 to $35.79 billion in 2026, with North America holding the largest share. The Business Research Company says rising surgery volumes, smarter infusion systems and tighter safety standards are shaping the next phase of growth.

Why it matters: - Intravenous therapy and vein access devices are central to fluid delivery, medication administration, blood transfusions and nutrition support in hospitals and clinics. - The market’s growth reflects broader demand for precise patient care, safer procedures and more advanced infusion technology. - Rising surgical volumes are adding direct demand for these devices during anesthesia, medication delivery and fluid management.

What happened: - The Business Research Company published a market report on the intravenous therapy and vein access devices sector on Aug. 13, 2026. - The market is projected to rise from $33.15 billion in 2025 to $35.79 billion in 2026. - The report projects the market will reach $48.1 billion by 2030. - North America held the largest share of the market in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available. - The full market report is also available.

The details: - The market’s 2025-2026 growth rate is 8.0%. - The forecast from 2026 to 2030 implies a 7.7% CAGR. - Recent growth has been supported by limited availability of advanced IV therapy devices, continued use of traditional catheters and needles, expanding hospital and clinic infrastructure, rising demand for blood-based products and drug administration, and stronger infection control awareness. - Future growth is expected to come from implantable ports, sophisticated infusion pumps, needleless connectors, IV administration sets, ambulatory surgical centers, smart monitoring and digital technologies. - The report also points to rising investment in patient safety and regulatory adherence. - Key product trends include peripheral and central venous access devices, safety-engineered needles and catheters, infusion pump upgrades, patient-controlled analgesia systems, and broader use in nutrition and medication delivery. - The report highlights a stronger focus on sterility, accuracy and regulatory compliance. - Intravenous therapy and vein access devices are defined as medical tools that deliver fluids, medications or nutrients directly into the bloodstream through veins using catheters and needles.

Between the lines: - Surgical activity is becoming a larger demand driver as elective procedures continue to grow. - ISAPS reported in June 2024 that total surgical and non-surgical procedures rose 3.4% in 2023 to 34.9 million. - ISAPS also reported surgical procedures increased 5.5%, with plastic surgeons performing more than 15.8 million surgeries and 19.1 million non-surgical treatments. - The four-year rise in procedures reached 40%, reinforcing the need for more IV access and infusion equipment. - The report’s emphasis on smart monitoring and safety-engineered devices suggests buyers are shifting toward products that reduce error and improve control, not just expand capacity.

What's next: - The market is expected to keep expanding through 2030 as ambulatory surgical centers grow and digital monitoring becomes more common. - More demand is likely for device lines that combine safety, precision and compliance with regulations. - The 2026 edition of the report adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics and updated technology and trend analysis.

The bottom line: - Intravenous therapy and vein access devices are moving from a basic hospital need to a technology-led growth market, with surgery volume, safety requirements and digital infusion systems driving the next phase.